No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
www.yuhan.co.krNo one on the platform currently holds 000100.KS.
No tracked institution reports a position in 000100.KS as of their last filing.
No one on the platform has traded 000100.KS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.5% | 3.0% | 3.4% | — | — | — |
| Rev. Growth % | 5.7% | 6.2% | ||||
| Profit Margin % | 8.9% | 6.2% | 6.9% | |||
| Free Cash Flow Margin % | -0.2% | -1.2% | -0.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.32T | +4.4% | $2086.37 | $1341.03–$3726.92 | — | 14 |
| 2027 | $2.54T | +9.3% | $2854.86 | $1651.24–$5251.25 | — | 14 |
| 2028 | $2.81T | +10.7% | $3939.55 | $3774.76–$4289.22 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $771.79 | $771.79 | +0.0% |
| 2026-04-30 | $263.47 | $289.13 | +9.7% |
| 2026-02-11 | $436.49 | $1456.13 | +233.6% |
| 2025-11-14 | $296.44 | $351.69 | +18.6% |
| 2025-07-30 | $289.45 | $608.67 | +110.3% |
| 2025-05-08 | $253.22 | $118.00 | -53.4% |
| 2025-02-14 | $320.35 | $-283.82 | -188.6% |
| 2024-10-28 | $583.66 | $499.00 | -14.5% |
| $3290.00 |
| +0.77% |
| $69.6B |
| — |
| 033270.KSKorea United Pharm Inc. | $17970.00 | -1.26% | $259.5B | — |
| 047920.KQHLB Pharmaceutical Co., Ltd | $6700.00 | +3.88% | $219.8B | — |
Source: Financial Modeling Prep · peers by sector/industry